secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2022-03-24T23:59:59+00:00
Accession:  0000950170-22-004547
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Athira reports FY2021 net loss $54.9M; ACT-AD Phase 2 data on track for Q2 2022
-------------------------------------------------------------------------------

- Net loss $54.9M ($1.49/share) vs $19.9M in 2020; R&D spend $42.8M, up from $13.3M.
- Cash & investments $319.7M as of Dec 31, 2021; cash used in ops $43.1M in 2021.
- Topline ACT-AD Phase 2 Alzheimer's data expected Q2 2022; LIFT-AD Phase 3 enrollment to complete Q3 2022.
- First patient dosed in SHAPE Phase 2 in Parkinson's dementia / DLB; ATH-1020 Phase 1 initiated.
- Appointed Grant Pickering and Dr. Michael Panzara to Board; expanded management team.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000095017022004547/0000950170-22-004547-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000095017022004547/atha-20220324.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-004547

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer